LexaGene (LXG) Stock Price, News & Analysis

Company Overview

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.

Key Stats

• Today's Range: C$0.10 to C$0.14
• 50-Day Range: C$0.11 to C$0.11
• 52-Week Range: C$0.07 to C$0.31
• Volume: 2.14 million shs
• Average Volume: 170,061 shs
• Market Capitalization: C$14.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LXG Stock Analysis - Frequently Asked Questions

How have LXG shares performed this year?

LexaGene's stock was trading at C$0.11 on January 1st, 2025. Since then, LXG stock has increased by 0.0% and is now trading at C$0.11.

How do I buy shares of LexaGene?

Shares of LXG stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of LexaGene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LexaGene investors own include Citius Pharmaceuticals (CTXR), Avino Silver & Gold Mines (ASM), Athersys (ATHX), Bionano Genomics (BNGO), EQT (EQT), Inovio Pharmaceuticals (INO) and NIO (NIO).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: CVE:LXG
• CIK: N/A
• Web: www.lexagene.com
• Phone: 800-215-1824
• Fax: N/A
• Employees: 41
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$8.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -339.54%
• Return on Assets: -120.21%

Debt

• Debt-to-Equity Ratio: 138.01
• Current Ratio: 1.39
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: C$110.93 thousand
• Price / Sales: 133.13
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 21.25
• Book Value: C$0.01 per share
• Price / Book: 10.50

Miscellaneous

• Outstanding Shares: 140,640,000
• Free Float: N/A
• Market Cap: C$14.77 million
• Optionable: Not Optionable
• Beta: 2.26